Low-dose AKT inhibitor miransertib (ARQ092) reduces the levels of phospho-AKT by approximately half in 83% of tissue samples of patients with Proteus syndrome, caused by gain-of-function mutations in AKT in the PI3KCA/AKT/mTOR pathway (117). The gene discussed is AKT1; the disease is Proteus syndrome.